Alder BioPharmaceuticals Inc. (NASDAQ:ALDR)’s share price dropped 2.3% during mid-day trading on Tuesday . The company traded as low as $30.14 and last traded at $30.52, with a volume of 166,320 shares. The stock had previously closed at $31.24.

ALDR has been the subject of a number of analyst reports. Brean Capital initiated coverage on Alder BioPharmaceuticals in a research report on Wednesday, April 20th. They set a “buy” rating and a $45.00 price objective for the company. Wells Fargo & Co. began coverage on Alder BioPharmaceuticals in a report on Thursday, April 21st. They issued an “outperform” rating for the company. Zacks Investment Research downgraded Alder BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Finally, Jefferies Group reiterated a “buy” rating and issued a $61.00 target price on shares of Alder BioPharmaceuticals in a report on Thursday, June 9th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $44.00.

The firm’s market capitalization is $1.51 billion. The firm has a 50 day moving average price of $27.97 and a 200 day moving average price of $25.41.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.04. The firm earned $0.11 million during the quarter, compared to analysts’ expectations of $1.14 million. During the same period in the prior year, the firm earned ($0.46) EPS. The company’s quarterly revenue was up 112900.0% on a year-over-year basis. Analysts anticipate that Alder BioPharmaceuticals Inc. will post ($2.76) EPS for the current year.

In other news, VP Jeffrey T. L. Smith sold 16,090 shares of the company’s stock in a transaction dated Friday, June 3rd. The stock was sold at an average price of $30.20, for a total value of $485,918.00. Following the completion of the transaction, the vice president now directly owns 16,090 shares in the company, valued at approximately $485,918. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Randall C. Schatzman sold 10,000 shares of the company’s stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $28.02, for a total value of $280,200.00. Following the completion of the transaction, the chief executive officer now owns 115,933 shares of the company’s stock, valued at $3,248,442.66. The disclosure for this sale can be found here.

Several institutional investors have recently bought and sold shares of ALDR. Nationwide Fund Advisors boosted its position in Alder BioPharmaceuticals by 103.6% in the fourth quarter. Nationwide Fund Advisors now owns 30,380 shares of the biopharmaceutical company’s stock worth $1,003,000 after buying an additional 15,457 shares during the last quarter. California Public Employees Retirement System boosted its position in Alder BioPharmaceuticals by 834.5% in the fourth quarter. California Public Employees Retirement System now owns 81,300 shares of the biopharmaceutical company’s stock worth $2,685,000 after buying an additional 72,600 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in Alder BioPharmaceuticals by 290.6% in the fourth quarter. Wells Fargo & Company MN now owns 269,774 shares of the biopharmaceutical company’s stock worth $8,911,000 after buying an additional 200,707 shares during the last quarter.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.